Neurocritical Care News

BOSTON — Results from the long-term RESTORE study show patients with Leber hereditary optic neuropathy with ND4 mutation who were treated with Lumevoq had sustained improvement of best-corrected visual acuity in both eyes.

Myrtelle Inc. has reported promising 6-month trial data for a recombinant adeno-associated virus vector-based investigational gene therapy for Canavan disease.

The FDA has approved Prospera, a spinal cord stimulation system to treat those with chronic intractable pain in the upper body and limbs.

The FDA has granted clearance to Neuspera Medical for its novel implantable system to treat chronic peripheral nerve pain.

In older adults with traumatic brain injury and acute subdural hematoma, early neurosurgical intervention resulted in the highest 30-day mortality rates, while delayed surgery yielded better outcomes.

Alzamend Neuro Inc. announced initiation of a phase 1/2a clinical trial for its proprietary immunotherapy vaccineALZN002 to treat mild to moderate dementia associated with Alzheimer’s disease.

Speed of processing training reduced the risk for future falls over 10 years in high-risk older adults, while reasoning and memory training did not reduce the likelihood of future falls in this population, according to research.

Patients with fibromyalgia were at greater risk for pain-related exacerbations of opioid use disorder, according to a study published in Pain.

JCR Pharmaceuticals Co. has entered into an agreement with AstraZeneca’s Rare Disease division, Alexion, to develop a novel therapeutic molecule for the treatment of neurodegenerative disease.

Hyperbaric oxygen therapy improved pain symptoms, quality of life and social and emotional function in adults with fibromyalgia after traumatic brain injury compared with pharmacologic intervention, according to research in PLOS One.